Labcorp Oncology Engager | Digital Event

Labcorp_Oncology_ CROPPED

Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning and Biomarker Targets to Maximise Clinical Development in Immuno-Oncology

This Engager has now run

Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning to Maximise Clinical Development in Immuno-Oncology

Immuno-Oncology drug development is being optimized through well-defined preclinical and clinical strategies focused on safety, endpoints and biomarker targets. Evolutions in the regulatory framework, a deeper understanding of cancer and re-defining key endpoints for success in Immuno-Oncology are combining to de-risk development.

This Labcorp Oncology Engager has been created as an exclusive online event to provide C-level Executives, Heads of Development, Pre-clinical & Clinical Operations leaderships of UK Immuno-Oncology biotechs with key learnings and takeaways on trial design concepts and biomarker considerations for optimising development strategy, optimising Go / No-Go decisions for agents in the preclinical space, regulatory framework considerations and accelerating the development of new IO therapies.

Join this Engager to identify emerging trends and best practices in achieving accelerated Immuno-Oncology drug development.

KEY TAKEAWAYS:

  • Translating the understandings in the preclinical space into clinical development
  • Evaluate the UK regulatory framework (and broader regulatory insights) to accelerate development into the clinic
  • Building foresight into clinical endpoint considerations and how to work with regulators on new, emerging endpoints
  • Key lessons learned in de-risking through “end-in-mind” approach into the clinical space

 

Following a Q&A, attendees can connect with key Labcorp Oncology executives and members to converse and dig a bit deeper into the topics covered throughout the session.

EXPERT SPEAKERS

Bruce Hamilton

Director of Biopharmaceutical Development

Labcorp Oncology

Kamal Veer Saini

Executive Medical Director, Oncology

Labcorp Oncology

Kenneth Morrison

Vice President, Regional Oncology Growth

Labcorp Oncology

Paul Baldrick

Executive Director, Nonclinical Regulatory Strategy, Product Development and Market Access Consulting

Labcorp Oncology

WHO SHOULD ATTEND

This is an exclusive limited-attendance event for C-level Executives, Heads of Development, Pre-clinical & Clinical Operations leadership of UK Immuno-Oncology biotechs who have recently entered early clinical development in the Oncology or Immuno-Oncology space and who are looking to get an overview of how to accelerate drug development.